Drug Approval | May 01, 2022
USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Subscribe To Our Newsletter & Stay Updated